AC
RLMD icon

Aristides Capital’s Relmada Therapeutics RLMD Stock Holding History

Aristides Capital’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-69,322
Closed -$242K – 234
2022
Q4 		$242K Buy
+69,322
New +$609K 0.12% 131

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Aristides Capital's RLMD Position: Q1 2023 in Review

Aristides Capital sold out of Relmada Therapeutics (RLMD) in Q1 2023, closing a stake of 69,322 shares — an estimated $242K sold.

Aristides Capital first reported a position in RLMD in Q4 2022 and held it in 1 quarter. The position peaked at $242K in Q4 2022. 91 funds tracked by Wall St. Rank hold RLMD as of Q1 2023.

  • Aristides Capital reported no remaining Relmada Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Aristides Capital sold 69,322 Relmada Therapeutics shares in Q1 2023, an estimated $242K.
  • Aristides Capital first reported a position in Relmada Therapeutics in Q4 2022 and held it in 1 quarter.
  • Aristides Capital's Relmada Therapeutics position peaked at $242K in Q4 2022.
  • 91 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2023.

Based on Aristides Capital's 13F filing for Q1 2023, filed 12 May 2023.